Inovio Stock Plummets Over 30% After Pricing $20 Million Dilutive Offering

Inovio Pharmaceuticals (NASDAQ:INO) shares plunged more than 30% in premarket trading Thursday after the biotechnology company announced the pricing of a public offering designed to raise approximately $20 million in gross proceeds. The offering price of $0.95 per unit signaled significant dilution for existing shareholders, triggering the sharp sell-off.

Offering Details

According to the company's announcement, the underwritten public offering consists of 21,052,632 shares of common stock. Each share is being sold together with accompanying warrants to purchase up to two additional shares of common stock, for a total of up to 42,105,264 warrants.

The combined offering price was set at $0.95 per share and its associated warrants. The warrants carry an exercise price of $1.10 per share. Gross proceeds are expected to be approximately $20 million, before deducting underwriting discounts and other expenses, and assuming the warrants are not exercised.

Piper Sandler is acting as the sole manager for the deal. Inovio also granted the underwriter a 30-day option to purchase an additional 3,157,894 shares and warrants for up to 6,315,788 shares. The offering is expected to close on or about July 31, 2026, subject to customary closing conditions.

Ad

Market Impact and Context

Investors reacted swiftly to the terms of the capital raise, sending the stock down 30.8% in premarket trading. Public offerings priced significantly below the current market price are dilutive, as they increase the total number of shares outstanding and reduce the ownership percentage of existing investors.

This type of financing is common for clinical-stage biotechnology companies like Inovio, which often require substantial capital to fund research and development. Inovio focuses on developing and commercializing DNA medicines to treat and protect against HPV-related diseases, cancer, and infectious diseases.